SCHEMBL24471024

SCHEMBL24471024

Cc1oc2ccc(OCc3ccccc3F)cc2c1C(=O)NC1CCN(CCO)C1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC26A4 O43511 4/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MAPT P10636 4/20 0.42
LMNA P02545 3/20 0.42
TSHR P16473 2/20 0.42
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 2/20 0.39
GAA P10253 2/20 0.39
ROCK1 Q13464 1/20 0.39
SCN3A Q9NY46 1/20 0.38
MET P08581 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29713018 1.00 SLC26A4 (0.47) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL24470750 0.91 SLC26A4 (0.50) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL29629640 0.89 SLC26A4 (0.45) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL29630081 0.89 SLC26A4 (0.45) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL24484946 0.89 SLC26A4 (0.45) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL24485720 0.88 SLC26A4 (0.44) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL29629810 0.88 SLC26A4 (0.44) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL30719746 0.88 RIPK1 (0.39) SLC26A4METRIPK1
SCHEMBL24484837 0.87 SLC26A4 (0.42) SLC26A4MEN1KMT2ACASP3SENP8
SCHEMBL24485012 0.87 SLC26A4 (0.42) SLC26A4MEN1KMT2ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed